Press coverage12 Jun 2023 10:21
Nuformix
While it may not be quite the right analogy to say that pharmaceutical development company Nuformix (NFX) is a phoenix rising from the ashes, it does seem to be NFX 2.0. The benefits of CEO Dan Gooding having returned to the company and running a tight ship are self-evident. Last month’s positive data revelation regarding flagship NXP002, being developed as a novel inhaled treatment for Idiopathic Pulmonary Fibrosis seem to be finally getting reflected via a rebound in the share price at the end of the week.